BlossomHill Therapeutics (NASDAQ:BLSM) Sets New 1-Year High - Time to Buy?

Key Points

• BlossomHill Therapeutics reached a new 52-week high of $20.62, though shares later traded near $19.80.
• Analyst sentiment is broadly positive: five analysts rate the stock Buy, one rates it Hold, and the consensus target is $32.20, with individual targets ranging from $32 to $36.
• The company remains unprofitable, with substantial losses projected through 2027, although losses are expected to narrow; recent insider purchases and upcoming oncology-focused presentations provide additional investor interest.

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM - Get Free Report) shares reached a new 52-week high on Friday . The stock traded as high as $20.62 and last traded at $19.80, with a volume of 45887 shares traded. The stock had previously closed at $20.02.

BlossomHill Therapeutics News Summary

Here are the key news stories impacting BlossomHill Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $35 price target, representing substantial potential upside from recent trading levels. Its estimates show quarterly losses narrowing from $0.92 per share in Q3 2026 to $0.69 per share by Q3–Q4 2027, while the projected full-year loss improves from $3.71 in 2026 to $2.99 in 2027. HC Wainwright earnings estimates and rating
• Positive Sentiment: BlossomHill announced upcoming presentations at the RAS-Targeted Drug Development Summit and the H.C. Wainwright Global Investment Conference. The events could increase investor awareness of its oncology pipeline and development strategy. BlossomHill conference presentation announcement
• Positive Sentiment: Several firms—including HC Wainwright, Guggenheim, Leerink Partners, LifeSci Capital and JPMorgan—recently initiated or expanded research coverage. Broader analyst attention can improve institutional visibility and trading interest. New analyst coverage
• Neutral Sentiment: Zacks Research upgraded its view of BLSM to Hold. The change suggests a more constructive stance than its prior rating, but a Hold is not a clearly bullish recommendation. Zacks rating update
• Negative Sentiment: Despite expected improvement, HC Wainwright still forecasts sizable losses through 2027, indicating that BlossomHill is not yet profitable and may remain dependent on financing or successful clinical development.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on BLSM shares. Leerink Partners started coverage on shares of BlossomHill Therapeutics in a research report on Tuesday. They set an "outperform" rating and a $36.00 target price on the stock. Wall Street Zen raised shares of BlossomHill Therapeutics to a "hold" rating in a research report on Saturday, August 15th. Zacks Research upgraded shares of BlossomHill Therapeutics to a "hold" rating in a report on Wednesday. HC Wainwright began coverage on BlossomHill Therapeutics in a report on Tuesday. They issued a "buy" rating and a $35.00 price objective for the company. Finally, Lifesci Capital assumed coverage on BlossomHill Therapeutics in a report on Tuesday. They issued an "outperform" rating and a $32.00 target price for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, BlossomHill Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $32.20.

BlossomHill Therapeutics Stock Performance

Insider Activity

In other news, General Counsel Vincent Liptak purchased 2,500 shares of the firm's stock in a transaction dated Friday, August 7th. The shares were purchased at an average price of $15.80 per share, with a total value of $39,500.00. Following the completion of the acquisition, the general counsel owned 109,212 shares in the company, valued at $1,725,549.60. This trade represents a 2.34% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director John P. Schmid acquired 6,000 shares of the company's stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average cost of $16.00 per share, with a total value of $96,000.00. Following the purchase, the director directly owned 6,000 shares of the company's stock, valued at $96,000. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders bought 1,573,900 shares of company stock worth $25,181,900.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company's lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source